Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Accured Expenses (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Change in Accured Expenses readings, the most recent being -$166000.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 91.66% to -$166000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.5 million, a 59.76% increase, with the full-year FY2025 number at -$5.3 million, up 57.47% from a year prior.
  • Change in Accured Expenses hit -$166000.0 in Q1 2026 for Atara Biotherapeutics, up from -$796000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $14.4 million in Q3 2022 to a low of -$8.8 million in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was -$2.0 million (2025), compared with a mean of -$1.3 million.
  • Biggest five-year swings in Change in Accured Expenses: crashed 6921.88% in 2023 and later surged 134.76% in 2024.
  • Atara Biotherapeutics' Change in Accured Expenses stood at -$3.5 million in 2022, then crashed by 91.24% to -$6.7 million in 2023, then surged by 69.5% to -$2.1 million in 2024, then surged by 61.32% to -$796000.0 in 2025, then surged by 79.15% to -$166000.0 in 2026.
  • The last three reported values for Change in Accured Expenses were -$166000.0 (Q1 2026), -$796000.0 (Q4 2025), and -$3.1 million (Q3 2025) per Business Quant data.